ClinicalTrials.gg
CompletedNCT05061979Updated Nov 21, 2022

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

A Phase 1 interventional study of BAY1747846 in Contrast Enhancement in Magnetic Resonance Imaging, sponsored by Bayer. Completed at 2 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-21.

Sponsored by Bayer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Mar 2022, 4 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

Researchers in this study want to learn how a new contrast agent for magnetic resonance imaging (MRI) called BAY1747846 moves into, through and out of the body (pharmacokinetics) after injection in participants with normal and impaired renal function. Impaired renal function is a condition where the kidneys do not work as well as they should.

BAY1747846 belongs to the class gadolinium-based contrast agents (GBCAs). The way the body removes GBCAs including BAY1747846 from the blood is through the kidneys. So, when the kidneys are not working normally, it takes longer to remove BAY1747846 out of the body.

The participants in this study will either have normal renal function, or will have mild or moderate impaired renal function. The participants will receive BAY1747846 one time through a needle into a vein.

During the study, the participants will visit the study site about 6 times. The participants will stay at the study site for up to 9 days. Each participant will be in the study for up to 7 months. During the study, the doctors will:

  • check the participants' overall health
  • take blood and urine samples
  • ask the participants about what medications they are taking and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
02

Conditions studied

  • Contrast Enhancement in Magnetic Resonance Imaging
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 79 years of age inclusive, at the time of signing the
  • Renally Impaired Participants and Disease Characteristics

    • Mildly or moderately decreased renal function, as assessed by estimated (eGFR). Mildly impaired renal function: eGFR: 60 up to 89 mL/min/1.73 m\^2 (inclusive); Moderately impaired renal function: eGFR: 30 up to 59 mL/min/1.73 m\^2 (inclusive)
    • Stable renal disease, i.e. a serum creatinine value determined 3 or more months before screening (e.g. during routine diagnostics) should not differ by more than 25% from the serum creatinine value determined at screening
  • Participants with normal renal function: Normal renal function, as assessed by eGFR ≥90 mL/min/1.73 m\^2
  • (BMI) within the range 18 - 40 kg/m\^2 (inclusive)
  • Body weight (bw) ≥ 45 kg
  • Study participants of must agree to use adequate when sexually active.
  • Male participants must agree not to donate sperm from the signing of the ICF until the follow-up visit on Day 12 (± 2d).

Exclusion criteria

Exclusion Criteria:

  • Any relevant disease (other than those related to renal impairment for the renal impaired participants) within 4 weeks prior to study drug administration including infections and acute gastro-intestinal diseases (vomiting, diarrhea, constipation) requiring medical treatment
  • Acute renal failure or acute nephritis within the past 2 years
  • Febrile illness within 1 week before study drug administration
  • diagnosed or treated within the past 5 years (hepatocellular carcinoma within the past 2 years). This does not include adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
  • Conditions associated with a risk of reactions as judged by the investigator
  • Any participant not able to produce urine and/or needing dialysis
  • Dialysis for acute renal failure within the previous 6 months prior to administration of study intervention
  • Contrast agent administration within one month prior to screening or during the screening period
  • Indication for , receiving cytotoxic therapy, immunosuppressive therapy, or other immunotherapy within 6 months prior to administration of study intervention
  • abnormalities in physical examination, , clinical chemistry, hematology, or urinalysis as judged by the investigator
  • Heart rate below 45 bpm or above 110 bpm
  • Systolic blood pressure below 90 mmHg or above 170 mmHg
  • Diastolic blood pressure below 45 or above 105 mmHg
  • Indication or evidence for long syndrome for all participants; additionally for participants with normal renal function: QT interval corrected using Fridericia's method (QTcF) > 470 msec
  • History of COVID-19 within 6 months prior to screening
  • Long COVID-19 syndrome or other clinically relevant COVID-19-related symptoms or sequela
  • Incomplete SARS-CoV-2 vaccination
  • Vaccination planned before completion of the last study visit
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Mild renal impairment

    Participants with mild renal impairment will receive a single dose of BAY1747846.

    Drug: BAY1747846

  • Experimental
    Moderate renal impairment

    Participants with moderate renal impairment will receive a single dose of BAY1747846.

    Drug: BAY1747846

  • Experimental
    Normal renal function

    Participants with normal renal function will receive a single dose of BAY1747846.

    Drug: BAY1747846

Interventions

  • Solution for intravenous (IV) injection, single dose

06

What researchers measure

Primary outcomes

  1. Area under the concentration versus time curve from zero to infinity of BAY1747846 after single dose administration (AUC)

    Time frame: Pre-dose until 7 days post-dose

  2. Maximum observed drug concentration of BAY1747846 in plasma after single dose administration (Cmax)

    Time frame: Pre-dose until 7 days post-dose

  3. Total body clearance of BAY1747846 normalized by body weight

    Time frame: Pre-dose until 7 days post-dose

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events

    Time frame: After administration of study intervention up to Day 12 (± 2 days)

  2. Number of participants with treatment-emergent adverse events categorized by severity

    Time frame: After administration of study intervention up to Day 12 (± 2 days)

07

Study locations

2 sites
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Alliance for Multispecialty Research, LLC - Knoxville
    Knoxville, Tennessee 37920, United States
08

References and documents

Publications

  • Fadini T, Sutter G, Klein S, Busemann E, Vendel E, Vis P, Heitmeier S, Frenzel T, Ebert W, Hofmann BM. Pharmacokinetics, Safety, and Dialyzability of Gadoquatrane in Patients With Impaired Renal Function: A Comprehensive Investigation Using Clinical Trial Data, Modeling and Simulation, and In Vitro Data. Invest Radiol. 2025 Nov 1;60(11):779-790. doi: 10.1097/RLI.0000000000001191. PubMed 40215351 ↗
  • Lohrke J, Berger M, Frenzel T, Hilger CS, Jost G, Panknin O, Bauser M, Ebert W, Pietsch H. Preclinical Profile of Gadoquatrane: A Novel Tetrameric, Macrocyclic High Relaxivity Gadolinium-Based Contrast Agent. Invest Radiol. 2022 Oct 1;57(10):629-638. doi: 10.1097/RLI.0000000000000889. Epub 2022 Jun 13. PubMed 35703267 ↗

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Mar 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Sep 30, 2021
StartActual
Oct 12, 2021
Primary completionActual
Mar 16, 2022
CompletionActual
Jul 14, 2022
Last update
Nov 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05061979
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 30, 2021
Start date
Oct 12, 2021
Primary completion
Mar 16, 2022
Completion
Jul 14, 2022
Last update
Nov 21, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadoquatrane

Start the discussion